Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity

Endocrine Reviews

Volumn 32, Issue 4, 2011, Pages 472-497

  David, Alessia ^a   Hwa, Vivian ^b   Metherell, Louise A ^a   Netchine, Iréne ^c,d,e   Camacho Hübner, Cecilia ^f   Clark, Adrian J L ^a   Rosenfeld, Ron G ^b   Savage, Martin O ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSERM   (France)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5B PROTEIN;

CHILD; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENETIC DAMAGE; GLUCONEOGENESIS; GROWTH DISORDER; GROWTH HORMONE INSENSITIVITY; GROWTH HORMONE RELEASE; GROWTH RATE; HOMOZYGOSITY; HORMONE BINDING; HORMONE RECEPTOR INTERACTION; HORMONE RESISTANCE; HUMAN; LIPOLYSIS; METABOLIC DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SHORT STATURE;

ANIMALS; CHILD; GROWTH; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; MUTATION; PHENOTYPE;

EID: 80052391845     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2010-0023     Document Type: Review

References (184)

1. Laron Z, Pertzelan A, Mannheimer S 1966 Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism? Isr J Med Sci 2:152-155.
2. Laron Z 2004 Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 89:1031-1044.
3. Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M 1984 Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci 20: 8-11.
4. Laron Z, Klinger B, Erster B, Anin S 1988 Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 2:1170-1172.
5. Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska JB, Underwood LE. 1991 Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 324:1483-1488.
6. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z, Wood WI 1989 Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci USA 86:8083-8087.
7. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goossens M 1989 Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 321:989-995.
8. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J 1994 Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 15:369-390.
9. Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hübner C 2006 Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2:395-407.
10. Salmon Jr WD, Daughaday WH 1957 A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med 49:825-836.
11. Green H, Morikawa M, Nixon T 1985 A dual effector theory of growth-hormone action. Differentiation 29:195-198.
12. Roberts Jr CT, Lasky SR, Lowe Jr WL, Seaman WT, Le-Roith D. 1987 Molecular cloning of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues. Mol Endocrinol 1:243-248.
13. Han VK, Lund PK, Lee DC, D'Ercole AJ 1988 Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. J Clin Endocrinol Metab 66:422-429.
14. Lowe Jr WL, Roberts Jr CT, Lasky SR, LeRoith D 1987 Differential expression of alternative 5' untranslated regions in mRNAs encoding rat insulin-like growth factor I. Proc Natl Acad Sci USA 84:8946-8950.
15. Lowe Jr WL, Lasky SR, LeRoith D, Roberts Jr CT 1988 Distribution and regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding alternative carboxyterminal E-peptides: evidence for differential processing and regulation in liver. Mol Endocrinol 2:528-535.
16. Isaksson OG, Jansson JO, Gause IA 1982 Growth hormonestimulates longitudinal bone growth directly. Science 216:1237-1239.
17. Nilsson A, Isgaard J, Lindahl A, Dahlström A, Skottner A, Isaksson OG. 1986 Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 233:571-574.
18. Isaksson OG, Lindahl A, Nilsson A, Isgaard J 1987 Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 8:426-438.
19. LeRoith D, Bondy C, Yakar S, Liu JL, Butler A 2001 The somatomedin hypothesis: 2001. Endocr Rev 22:53-74.
20. Sjö gren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tö rnell J, Isaksson OG, Jansson JO, Ohlsson C 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088-7092.
21. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329.
22. Wu Y, Sun H, Yakar S, LeRoith D 2009 Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology 150: 4395-4403.
23. Kaplan SA, Cohen P 2007 The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 92:4529-4535.
24. Ohlsson C, Mohan S, Sjögren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J 2009 The role of liverderived insulin-like growth factor-I. Endocr Rev 30:494-535.
25. Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR 2000 Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci USA 97:6868-6873.
26. Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG 2004 Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 350:570-577.
27. Derr MA, Fang P, Sinha SK, Ten S, Hwa V, Rosenfeld RG 2011AnovelY332Cmissense mutation in the intracellular domain of the human growth hormone receptor (GHR) does not alter STAT5b signaling: redundancy of GHR in-tracellular tyrosines involved in STAT5b signaling. Horm Res Paediatr 75:187-199.
28. Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hübner C, Savage MO, Bidlingmaier M, Bidlingmaier CM, Clark AJ, Ross RJ, Webb SM 2004 Growth hormone insensitivity syndrome due to a growth hormone receptor truncated after box 1 resulting in isolated failure of STAT 5 signal transduction. J Clin Endocrinol Metab 89:1259-1266.
29. Jin H, Lanning NJ, Carter-Su C 2008 JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol Endocrinol 22:1825-1841.
30. Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, Millard K, Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ 2008 An agonistinduced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol 10:740-747.
31. Barclay JL, Kerr LM, Arthur L, Rowland JE, Nelson CN, Ishikawa M, d'Aniello EM, White M, Noakes PG, Waters MJ 2010 In vivo targeting of the growth hormone receptor (GHR) box1 sequence demonstrates that the GHR does not signal exclusively through JAK2. Mol Endocrinol 24: 204-217.
32. Chia DJ, Varco-Merth B, Rotwein P 2010 Dispersed chromosomal Stat5b-binding elements mediate growth hormoneactivated insulin-like growth factor-I gene transcription. J Biol Chem 285:17636-17647.
33. Wang Y, Jiang H 2005 Identification of a distal STATbinding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem 280:10955-10963.
34. Adams TE, Epa VC, Garrett TP, Ward CW. 2000 Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093.
35. Fowden AL 2003 The insulin-like growth factors and fetoplacental growth. Placenta 24:803-812.
36. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A 2001 Roles of growth hormone and insulin-like growth factor-1 in mouse postnatal growth. Dev Biol 229:141-162.
37. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ 1996 Intrauterine growth retardation and post-natal growth failure associated with deletion of the insulin-like growth factor-I gene. N Engl J Med 335:1363-1367.
38. Netchine I, Azzi S, Le Bouc Y, Savage MO 2011 IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Clin Endocrinol Metab 25:181-190.
39. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF, Breuning MH, Romijn JA, Karperien M, Wit JM 2006 A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab 91:3062-3470.
40. Ballesteros M, Leung KC, Ross RJ, Iismaa TP, Ho KK. 2000 Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues. J Clin Endocrinol Metab 85:2865-2871.
41. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ 2005 Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12:814-821.
42. Brooks AJ, Waters MJ 2010 The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 6:515-525.
43. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, Carter-Su C 1993 Identification of JAK2 as a growth hormone receptor-associated kinase. Cell 74:237-244.
44. Diniz ET, JorgeAA, Arnhold IJ, Rosenbloom AL, Bandeira F 2008 Novel missense mutation (pY113X) in the human growth hormone receptor gene in a Brazilian patient with Laron syndrome. [in Portuguese] Arq Bras Endocrinol Metabol 52:1264-1271.
45. Baumann G 2002 Genetic characterization of growth hormone deficiency and resistance: implications for treatment with recombinant growth hormone. Am J Pharmacogenomics 2:93-111.
46. Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, Chew SL, Clark AJ 2001 Pseudoexon activation as a novel mechanism for disease resulting in atypical growth hormone insensitivity. Am J Hum Genet 69: 641-646.
47. Maamra M, Milward A, Esfahani HZ, Abbott LP, Metherell LA, Savage MO, Clark AJ, Ross RJ 2006 A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signalling. J Endocrinol 188:251-261.
48. Akker SA, Misra S, Aslam S, Morgan EL, Smith PJ, Khoo B, Chew SL 2007 Pre-spliceosomal binding of U1 small nuclear ribonucleoprotein (RNP) and heterogenous nuclear RNP E1 is associated with suppression of a growth hormone receptor pseudoexon. Mol Endocrinol 21:2529-2540.
49. David A, Camacho-Hübner C, Bhangoo A, Rose SJ, Miraki-Moud F, Akker SA, Butler GE, Ten S, Clayton PE, Clark AJ, SavageMO, Metherell LA. 2007Anintronicgrowthhormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes. J Clin Endocrinol Metab 92:655-659.
50. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, NormanMR 1997 A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 16: 13-14.
51. Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, Chihara K 1998 Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 83:531-537.
52. Fang P, Riedl S, Amselem S, Pratt KL, Little BM, Haeusler G, Hwa V, Frisch H, Rosenfeld RG 2007 Primary growth hormone (GH) insensitivity and insulin-like growth factor deficiency caused by novel compound heterozygous mutations of the GH receptor gene: genetic and functional studies of simple and compound heterozygous states. J Clin Endocrinol Metab 92:2223-2231.
53. Aisenberg J, Auyeung V, Pedro HF, Sugalski R, Chartoff A, Rothenberg R, Derr MA, Hwa V, Rosenfeld RG 2010 Atypical GH insensitivity syndrome and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the GH receptor, including a novel frameshift mutation affecting the intracellular domain. Horm Res Paediatr 74:406-411.
54. Aalbers AM, Chin D, Pratt KL, Little BM, Frank SJ, Hwa V, Rosenfeld RG 2009 Extreme elevation of serum growth hormone-binding protein concentrations resulting from a novel heterozygous splice site mutation of the growth hormone receptor gene. Horm Res 71:276-284.
55. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V 2007 Defects in growth hormone receptor signaling. Trends Endocrinol Metab 18:134-141.
56. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Rosenfeld RG 2003 Growth-hormone insensitivity associated with a STAT5b mutation. N Engl J Med 349:1139-1147.
57. Hwa V, Camacho-Hübner C, Little BM, David A, Metherell LA, El-Khatib N, Savage MO, Rosenfeld RG 2007 Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res 68:218-224.
58. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, Ornani A, Paz R, Rivarola MA, Zelazko M, Belgorosky A. 2006 Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 118:e1584-e1592.
59. Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG 2005 Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 90:4260-4266.
60. Vidarsdottir S, Walenkamp MJ, PereiraAM, KarperienM, van Doorn J, van Duyvenvoorde HA, White S, Breuning MH, Roelfsema F, Kruithof MF, van Dissel J, Janssen R, Wit JM, Romijn JA 2006 Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab 91:3482-3485.
61. Rubinstein A, Bernstein LJ, Charytan M, Krieger BZ, Ziprkowski M 1988 Corticosteroid treatment for pulmonary lymphoid hyperplasia in children with the acquired immunodeficiency syndrome. Pediatr Pulmonol 4:13-17.
62. Hwa V, Little B, Kofoed EM, Rosenfeld RG 2004 Transcriptional regulation of insulin-like growth factor-I by interferon-γ requires STAT-5b. J Biol Chem279:2728-2736.
63. Fang P, KofoedEM, LittleBM, WangX, Ross RJ, Frank SJ, Hwa V, Rosenfeld RG 2006 A mutant signal transducer and activator of transcription 5b, associated with growth hormone insensitivity and insulin-like growth factor-I deficiency, cannot function as a signal transducer or transcription factor. J Clin Endocrinol Metab 91:1526-1534.
64. Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, Teper A, Gaillard M, Heinrich J, Krensky AM, Rosenfeld RG, Lewis DB 2006 Cutting edge: decreased accumulation and regulatory function ofCD4+CD25high T cells in human STAT5b deficiency. J Immunol 177: 2770-2774.
65. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell Jr JE, Kuriyan J 1998 Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:827-839.
66. Chia DJ, Subbian E, Buck TM, Hwa V, Rosenfeld RG, Skach WR, Shinde U, Rotwein P 2006 Aberrant folding of a mutant STAT5b causes growth hormone insensitivity and proteasomal dysfunction. J Biol Chem 281:6552-6558.
67. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, Chapgier A, Eidenschenk C, Eid P, Al Ghonaium A, Tufenkeji H, Frayha H, Al-Gazlan S, Al-Rayes H, Schreiber RD, Gresser I, Casanova JL. 2003 Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 33:388-391.
68. Lappalainen I, Thusberg J, Shen B, Vihinen M 2008 Genome wide analysis of pathogenic SH2 domain mutations. Proteins 72:779-792.
69. Pugliese-Pires PN, Tonelli CA, Dora JM, Silva PC, Czepielewski M, Simoni G, Arnhold IJ, Jorge AA 2010 A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. Eur J Endocrinol 163: 349-355.
70. Martinez A, Scaglia PA, Rivas M, Bezrodnik L, Gaillard MI, Heinrich JJ, Ballerini MG, Jasper HG, Domene HM 2007 Novel STAT5b gene mutation in a patient presenting GH insensitivity and immunodeficiency. Horm Res 68(Suppl 1):33.
71. Boyanovsky A, Lozano A, Testa G, Munoz L, Marino R, Bernasconi A, Belgorosky A, Miras M, Growth hormone insensitivity and immunodeficiency: mutation in the STAT5B gene. Proc 8th Joint Meeting of the Lawson Wilkins Pediatric Endocrine Society/European Society for Paediatric Endocrinology, NewYork, 2009 (Abstract P01-067).
72. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, PattonMA, Kucherlapati RS, GelbBD 2001 Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468.
73. Brasil AS, Pereira AC, Wanderley LT, Kim CA, Malaquias AC, Jorge AA, Krieger JE, Bertola DR 2010 PTPN11 and KRAS gene analysis in patients with Noonan and Noonanlike syndromes. Genet Test Mol Biomarkers 14:425-432.
74. Kim SO, Jiang J, Yi W, Feng GS, Frank SJ 1998 Involvement of the Src homology 2-containing tyrosine phosphatase SHP2 in growth hormone signaling. J Biol Chem 273: 2344-2354.
75. Stofega MR, Herrington J, Billestrup N, Carter-Su C 2000 Mutation of the SHP2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 14:1338-1350.
76. Binder G, Neuer K, Ranke MB, Wittekindt NE 2005 PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377-5381.
77. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y 2006 Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 91:300-306.
78. Binder G 2009 Response to growth hormone in short children with Noonan syndrome: correlation to genotype. Horm Res 72(Suppl 2):52-56.
79. Woods KA, Camacho-Hübner C, Bergman RN, Barter D, Clark AJ, Savage MO 2000 Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 85:1407-1411.
80. Camacho-Hübner C, Woods KA, Miraki-Moud F, Hindmarsh PC, Clark AJ, Hansson Y, Johnston A, Baxter RC, Savage MO. 1999 Effects of recombinant human insulin-like growth factor-I (IGF-I) therapy on the growth hormone-IGF system of a patient with partial IGF-I gene deletion. J Clin Endocrinol Metab 84:1611-1616.
81. Bonapace G, Concolino D, Formicola S, Strisciuglio P 2003 A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 40:913-917.
82. Walenkamp MJ, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM 2005 Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab90:2855-2864.
83. Netchine I, Azzi S, Houang M, Seurin D, Perin L, Ricort JM, Daubas C, Legay C, Mester J, Herich R, Godeau F, Le Bouc Y 2009 Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGF-1 mutation demonstrates its critical role in growth and brain development. J Clin Endocrinol Metab 94:3913-3921.
84. Netchine I, Rossignol S, DufourgMN, Azzi S, Rousseau A, Perin L, Houang M, Steunou V, Esteva B, Thibaud N, Demay MC, Danton F, Petriczko E, Bertrand AM, Heinrichs C, Carel JC, Loeuille GA, Pinto G, Jacquemont ML, Gicquel C, Cabrol S, Le Bouc Y 2007 11p15 imprinting center region 1 loss of methylation is a common and specific cause of typical Russell-Silver syndrome: clinical scoring system and epigenetic-phenotypic correlations. J Clin Endocrinol Metab 92:3148-3154.
85. van Gemund JJ, Laurent de Angulo MS, van Gelderen HH 1970 Familial prenatal dwarfism with elevated serum immuno-reactive growth hormone levels and endorgan unresponsiveness. Maandschr Kindergeneeskd 37:372-382.
86. Coutinho DC, Coletta RR, Costa EM, Pachi PR, Boguszewski MC, Damiani D, Mendonca BB, Arnhold IJ, Jorge AA 2007 Polymorphisms identified in the upstream core polyadenylation signal of IGF1gene exon 6 do not cause preand postnatal growth impairment. J Clin Endocrinol Metab 92:4889-4892.
87. van Duyvenvoorde HA, van Setten PA, Walenkamp MJ, van Doorn J, Koenig J, Gauguin L, Oostdijk W, Ruivenkamp CA, Losekoot M, Wade JD, De Meyts P, Karperien M, NoordamC, WitJ M. 2010 Short stature associated with a novel heterozygous mutation in the insulin-like growth factor 1 gene. J Clin Endocrinol Metab 95:E363-E367.
88. van Duyvenvoorde HA, van Doorn J, Koenig J, Gauguin L, Oostdijk W, Wade JD, Karperien M, Ruivenkamp CA, Losekoot M, van Setten PA, Walenkamp MJ, Noordam C, De Meyts P, Wit JM 2011 The severe short stature in two siblings with a heterozygous IGF1 mutation is not caused by a dominant negative effect of the putative truncated protein. Growth Horm IGF Res 21:44-50.
89. Fuqua JS, Hwa V, Rosenfeld RG, Identification of a heterozygous IGF-1 gene splice mutation. Proc 8th Joint Meeting of the Lawson Wilkins Pediatric Endocrine Society/European Society for Paediatric Endocrinology, New York, 2009 (Abstract P01-075).
90. Leong SR, Baxter RC, Camerato T, Dai J, Wood WI 1992 Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex. Mol Endocrinol 6:870-876.
91. Ooi GT, Cohen FJ, Tseng LY, Rechler MM, Boisclair YR 1997 Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALSpromoter activity in rat liver. Mol Endocrinol 11:997-1007.
92. Baxter RC 1994 Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42: 140-144.
93. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT 2001 The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 170:63-70.
94. Domené HM, Scaglia PA, Lteif A, Mahmud FH, Kirmani S, Frystyk J, Bedecarrás P, Gutiérrez M, Jasper HG 2007 Phenotypic effects of null and haploinsufficiency of acidlabile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab 92:4444-4450.
95. Domené HM, Hwa V, Argente J, Wit JM, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG. 2009 Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 72:129-141.
96. David A, Rose SJ, Miraki-Moud F, Metherell LA, Savage MO, Clark AJ, Camacho-Hübner C 2010 Acid-labile subunit deficiency and growth failure: description of two novel cases. Horm Res Paediatr 73:328-334.
97. Heath KE, Argente J, Barrios V, Pozo J, Díaz-Gonzá lez F, Martos-Moreno GA, Caimari M, Gracia R, Campos-Barros A 2008 Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating insulin growth factor (IGF)-I, IGF binding protein-3 levels, and hyperinsulinemia. J Clin Endocrinol Metab 93:1616-1624.
98. Fofanova-Gambetti OV, Hwa V, Wit JM, Domene HM, Argente J, Bang P, Högler W, Kirsch S, Pihoker C, Chiu HK, Cohen L, Jacobsen C, Jasper HG, Haeusler G, Campos-Barros A, Gallego-Gómez E, Gracia-Bouthelier R, van Duyvenvoorde HA, Pozo J, Rosenfeld RG 2010 Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the International Acid-Labile Subunit Consortium. J Clin Endocrinol Metab 95:4184-4191.
99. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, KiessW, Klammt J, Kratzsch J, Osgood D, Pfäffle R, Raile K, Seidel B, Smith RJ, Chernausek SD 2003 IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349: 2211-2222.
100. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi J, Ohtsuka Y, Hisatome I, Ninomoya H, Nanba E, Fukushima T, Takahashi S 2005 Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 90:4679-4687.
101. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts Jr CT, Hwa V, Rosenfeld RG 2009 Familial short stature caused by haploinsufficiency of the insulin-like growth factor I receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin Endocrinol Metab 94:1740-1747.
102. Inagaki K, Tiulpakov A, Rubtsov P, Sverdlova P, Peterkova V, Yakar S, Terekhov S, LeRoith D. 2007Afamilial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab 92:1542-1548.
103. Wallborn T, Wüller S, Klammt J, Kruis T, Kratzsch J, Schmidt G, SchlickeM, Müller E, van de Leur HS, KiessW, Pfä ffle R 2010 A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95:2316-2324.
104. Kruis T, Klammt J, Galli-Tsinopoulou A, Wallborn T, Schlicke M, Müller E, Kratzsch J, Kö rner A, Odeh R, Kiess W, Pfä ffle R. 2010 Heterozygous mutation within a kinaseconserved motif of the insulin-like growth factor I receptor causes intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 95:1137-1142.
105. Ester WA, van Duyvenvoorde HA, de Wit CC, Broekman AJ, Ruivenkamp CA, Govaerts LC, Wit JM, Hokken-Koelega AC, Losekoot M 2009 Two short children born small for gestational age with insulin-like growth factor 1 receptor haploinsufficiency illustrate the heterogeneity of its phenotype. J Clin Endocrinol Metab 94:4717-4727.
106. Kowarski AA, Schneider J, Ben-Galim E, Weldon VV, Daughaday WH 1978 Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 47:461-464.
107. Takahashi Y, Kaji H, Okimura Y, Goji K, Abe H, Chihara K. 1996 Short stature caused by a mutant growth hormone. N Engl J Med 334:432-436.
108. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, Kaji H, Okimura Y, Abe H, Tanaka T, Chihara K 1997 Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest 100:1159-1165.
109. Besson A, Salemi S, Deladoëy J, Vuissoz JM, Eblé A, Bidlingmaier M, Bürgi S, Honegger U, Flück C, Mullis PE 2005 Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). J Clin Endocrinol Metab 90: 2493-2499.
110. Cogan JD, Phillips 3rd JA 2006 GH1 gene deletions and IGHD type 1A. Pediatr Endocrinol Rev 3:480-488.
111. Phillips 3rd JA, Hjelle BL, Seeburg PH, Zachmann M. 1981 Molecular basis for familial isolated growth hormone deficiency. Proc Natl Acad Sci USA 78:6372-6375.
112. Procter AM, Phillips 3rd JA, Cooper DN 1998 The molecular genetics of growth hormone deficiency. Hum Genet 103:255-272.
113. Alatzoglou KS, Dattani M T. 2010 Genetic causes and treatment of isolated growth hormone deficiency-an update. Nat Rev Endocrinol 6:562-576.
114. Riedl S, Frisch H 2006 Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab 19:229-236.
115. Speiser PW, White PC 2003 Congenital adrenal hyperplasia. N Engl J Med 349:776-788.
116. Woods KA, Dastot F, Preece MA, Clark AJ, Postel-Vinay MC, Chatelain PG, RankeMB, Rosenfeld RG, Amselem S, Savage MO 1997 Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 82:3529-3535.
117. Burren CP, Woods KA, Rose SJ, Tauber M, Price DA, Heinrich U, Gilli G, Razzaghy-Azar M, Al-Ashwal A, Crock PA, Rochiccioli P, YordamN, RankeMB, Chatelain PG, Preece MA, Rosenfeld RG, Savage MO. 2001 Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome. Horm Res 55: 125-130.
118. Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond Jr FB, Rosenfeld RG 1993 Growth hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 76:417-423.
119. Blum WF, Cotterill AM, Postel-Vinay MC, Ranke MB, Savage MO, Wilton P 1994 Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr Suppl 399:117-124.
120. Cotterill AM, Holly JM, Taylor AM, Davies SC, Coulson VJ, PreeceMA, Wass JA, Savage MO. 1992 The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab 74: 56-63.
121. Burren CP, Wanek D, Mohan S, Cohen P, Guevara-Aguirre J, Rosenfeld RG 1999 Serum levels of insulin-like growth factor binding proteins in Ecuadorean children with growth hormone insensitivity. Acta Paediatr Suppl 88:185-191; discussion 192.
122. Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD. 1997 Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 90:2680-2689.
123. Lemahieu V, Gastier JM, Francke U. 1999 Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat 14:54-66.
124. Savage MO, Burren CP, Rosenfeld RG 2010 The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) 72:721-728.
125. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM, on behalf of the 2007 ISS Consensus Workshop participants 2008 Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 93: 4210-4217.
126. Growth Hormone Research Society 2000 Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary Statement of the GH Research Society. J Clin Endocrinol Metab 85:3990-3993.
127. Cianfarani S, Liguori A, Boemi S, Maghnie M, Iughetti L, Wasniewska M, Street ME, Zucchini S, Aimaretti G, Germani D 2005 Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP-3) assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to lowGHdependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab 90:6028-6034.
128. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebaek NE 1994 Serum insulinlike growth factor-I in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 78: 744-752.
129. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE. 1995 Serum levels of insulinlike growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index and pubertal maturation. J Clin Endocrinol Metab 80:2534-2542.
130. Rosenfeld RG, Kemp SF, Hintz RL 1981 Constancy of somatomedin response to growth hormone treatment of hypopituitary dwarfism, and lack of correlation with growth rate. J Clin Endocrinol Metab 53:611-617.
131. Rosenfeld RG 2005 The IGF system: new developments relevant to pediatric practice. In: Cianfarani S, Clemmons DR, Savage MO, eds. IGF-I and IGF binding proteins: basic research and clinical management. Endocrine Development, vol 9. Basel, Switzerland: Karger; 1-10.
132. Selva KA, Buckway CK, Sexton G, Pratt KL, Tjoeng E, Guevara-Aguirre J, Rosenfeld RG. 2003 Reproducibility in patterns of IGF generation tests with special reference to idiopathic short stature. Horm Res 60:237-246.
133. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM; MS301 Study Group 2010 Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab 95:611-619.
134. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG 2001 The IGF-I generation test revisited: a marker of GH sensitivity. J Clin Endocrinol Metab 86: 5176-5183.
135. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB 2002 Poor reproducibility of the IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab 87:469-472.
136. Shevah O, Borrelli P, Rubinstein M, Laron Z 2003 Identification of two novel mutations in the human growth hormone receptor gene. J Endocrinol Invest 26:604-608.
137. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S 2003 Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J Clin Endocrinol Metab 88:1705-1710.
138. Amselem S, Sobrier ML, Duquesnoy P, Rappaport R, Postel-VinayMC, GourmelenM, Dallapiccola B, GoossensM 1991 Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism. J Clin Invest 87:1098-1102.
139. Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier ML, Valleix S, Goossens M 1993 Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet 2:355-359.
140. Berg MA, Argente J, Chernausek S, Gracia R, Guevara-Aguirre J, Hopp M, Pérez-Jurado L, Rosenbloom A, Toledo SP, Francke U 1993 Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 52: 998-1005.
141. Putzolu M, Meloni A, Loche S, Pischedda C, Cao A, Moi P 1997 A homozygous nonsense mutation of the human growth hormone receptor gene in a Sardinian boy with Laron-type dwarfism. J Endocrinol Invest 20:286-288.
142. SobrierML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S 1997 Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab 82:435-437.
143. Tiulpakov A, Rubtsov P, Dedov I, Peterkova V, Bezlepkina O, Chrousos GP, Hochberg Z 2005 A novel C-terminal growth hormone receptor (GHR) mutation results in impaired GHR-STAT5 but normal STAT-3 signaling. J Clin Endocrinol Metab 90:542-547.
144. Goddard AD, Covello R, Luoh SM, Clackson T, AttieKM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM 1995 Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 333:1093-1098.
145. Fassone L, Corneli G, Bellone S, Camacho-Hübner C, Aimaretti G, Cappa M, Ubertini G, Bona G 2007 Growth hormone receptor gene mutations in two Italian patients with Laron syndrome. J Endocrinol Invest 30:417-420.
146. Fang P, Girgis R, Little BM, Pratt KL, Guevara-Aguirre J, Hwa V, Rosenfeld RG 2008 Growth hormone (GH) insensitivity and insulin-like growth factor-I deficiency in Inuit subjects and an Ecuadorian cohort: functional studies of two codon 180 GH receptor gene mutations. J Clin Endocrinol Metab 93:1030-1037.
147. Berg MA, Peoples R, Pérez-Jurado L, Guevara-Aguirre J, Rosenbloom AL, Laron Z, Milner RD, Francke U 1994 Receptor mutations and haplotypes in growth hormone receptor deficiency: a global survey and identification of the Ecuadorean E180splice mutation in an oriental Jewish patient. Acta Paediatr Suppl 399:112-114.
148. Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, Okimura Y, Abe H, Chihara K 1997 Novel compound heterozygous mutations of growth hormone(GH)receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab 82:3705-3709.
149. Quinteiro C, Castro-Feijoo L, Loidi L, Barreiro J, de la Fuente M, Dominguez F, Pombo M. 2002 Novel mutation involving the translation initiation codon of the growth hormone receptor gene (GHR) in a patient with Laron syndrome. J Pediatr Endocrinol Metab 15:1041-1045.
150. Chen X, Song F, Dai Y, Bao X, Jin Y 2003 A novel mutation of the growth hormone receptor gene (GHR) in a Chinese girl with Laron syndrome. J Pediatr Endocrinol Metab 16:1183-1189.
151. Ying YQ, Wei H, Cao LZ, Lu JJ, Luo XP 2007 Clinical features and growth hormone receptor gene mutations of patients with Laron syndrome from a Chinese family. Zhongguo Dang Dai Er Ke Za Zhi 9:335-338.
152. Shevah O, Rubinstein M, Laron Z 2004 Molecular defects of the growth hormone receptor gene, including a new mutation, in Laron syndrome patients in Israel: relationship between defects and ethnic groups. Isr Med Assoc J 6:630-633.
153. Arman A, Yüksel B, Coker A, Sarioz O, Temiz F, Topaloglu AK 2010 Novel growth hormone receptor gene mutation in a patient with Laron syndrome. J Pediatr Endocrinol Metab 23:407-414.
154. Walker JL, Crock PA, Behncken SN, RowlinsonSW, Nicholson LM, Boulton TJ, Waters MJ 1998 A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to longterm treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 83:2554-2561.
155. Sanchez JE, Perera E, Baumbach L, Cleveland WW 1998 Growth hormone receptor mutations in children with idiopathic short stature. J Clin Endocrinol Metab 83:4079-4083.
156. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M 1994 A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J 13:1386-1395.
157. Yang C, Chen JY, Lai CC, Lin HC, Yeh GC, Hsu HH. 2004 Clinical, biochemical and molecular investigations of three Taiwanese children with Laron syndrome. J Pediatr Endocrinol Metab 17:165-171.
158. Wojcik J, Berg MA, Esposito N, Geffner ME, Sakati N, ReiterEO, DowerS, Francke U, Postel-VinayMC, Finidori J 1998 Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor. J Clin Endocrinol Metab 83:4481-4489.
159. Oh PS, Kim IS, Moon Y H, Amolecular genetic study on the two Korean patients with Laron syndrome. Program of the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1999, p 140 (Abstract P1-26).
160. Enberg B, Luthman H, Segnestam K, Ritzén EM, Sundström M, Norstedt G 2000 Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation. Eur J Endocrinol 143:71-76.
161. Tauber MT, Porra V, Dastot F, Molinas C, Amselem S, Cholin S, Rochiccioli P, Bieth E 1998 Heterozygous mutation in the WSXWS equivalent motif of the growth hormone receptor in a child with poor response to growth hormone therapy. Growth Horm IGF Res 8:211-216.
162. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB 2004 The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of theGHreceptor causing Laron syndrome: suppression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration. Clin Endocrinol (Oxf) 60:36-40.
163. KouK, Lajara R, Rotwein P 1993Aminoacid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab 76:54-59.
164. Iida K, Takahashi Y, Kaji H, Onodera N, Takahashi MO, Okimura Y, Abe H, Chihara K 1999 The C422F mutation of the growth hormone receptor gene is not responsible for short stature. J Clin Endocrinol Metab 84:4214-4219.
165. Goddard AD, Dowd P, Chernausek S, Geffner M, Gertner J, Hintz R, Hopwood N, Kaplan S, Plotnick L, Rogol A, Rosenfield R, Saenger P, Mauras N, Hershkopf R, Angulo M, Attie K 1997 Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. J Pediatr 131:S51-S55.
166. Saenger PH 1999 Partial growth hormone insensitivity-idiopathic short stature is not always idiopathic. Acta Paediatr Suppl 88:194-198.
167. Chujo S, Kaji H, Takahashi Y, Okimura Y, Abe H, Chihara K 1996 No correlation of growth hormone receptor gene mutation P561T with body height. Eur J Endocrinol 134:560-562.
168. Arman A, Ozon A, Isguven PS, Coker A, Peker I, Yordam N 2008 Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism. J Pediatr Endocrinol Metab 21:47-58.
169. Otsuka T, Iwatani N, KodamaM, SakakidaM, ShichiriM, Jinno Y, Niikawa N, Miike T 1997 The growth hormone receptor gene mutation of a Japanese patient with Laron syndrome. Jpn J Hum Genet 42:323-329.
170. Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U 1992 Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutat 1:24-32.
171. Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, Stein S, Eidson M, Parks JS, Cleveland W 1997 Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab 82:444-451.
172. David A, Miraki-Moud F, Shaw NJ, SavageMO, Clark AJ, Metherell LA 2010 Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity. Eur J Endocrinol 162:37-42.
173. Shevah O, Nunez O, Rubinstein M, Laron Z. 2002 Intronic mutation in the growth hormone receptor gene in a Peruvian girl with Laron syndrome. J Pediatr Endocrinol Metab 15:1039-1040.
174. Woods KA, Fraser NC, Postel-Vinay MC, Savage MO, Clark AJ 1996Ahomozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GHbinding protein. J Clin Endocrinol Metab 81:1686-1690.
175. Besson A, Salemi S, Eblé A, Joncourt F, Gallati S, Jorge AA, Mullis PE 2004 Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol 150:635-642.
176. Meacham LR, Brown MR, Murphy TL, Keret R, Silbergeld A, Laron Z, Parks JS 1993 Characterization of a noncontiguous gene deletion of the growth hormone receptor in Laron's syndrome. J Clin Endocrinol Metab 77: 1379-1383.
177. Gastier JM, Berg MA, Vesterhus P, Reiter EO, Francke U 2000 Diverse deletions in the growth hormone receptor gene cause growth hormone insensitivity syndrome. Hum Mutat 16:323-333.
178. Yamamoto H, Kouhara H, Iida K, Chihara K, Kasayama S 2008 A novel growth hormone receptor gene deletion mutation in a patient with primary growth hormone insensitivity syndrome (Laron syndrome). Growth Horm IGF Res 18:136-142.
179. Gennero I, Edouard T, Rashad M, Bieth E, Conte-Aurio F, Marin F, Tauber M, Salles JP, El Kholy M 2007 Identification of a novel mutation in the human growth hormone receptor gene (GHR) in a patient with Laron syndrome. J Pediatr Endocrinol Metab 20:825-831.
180. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG 2006 Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 91:1826-1831.
181. van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doorn J, Gerver WJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus AR 2008 Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 159:113-120.
182. Fofanova-Gambetti OV, Hwa V, Kirsch S, Pihoker C, Chiu HK, Högler W, Cohen LE, Jacobsen C, Derr MA, Rosenfeld RG 2009 Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-I/IGFBP-3 deficiency in children of different ethnic origins. Horm Res 71:100-110.
183. Bang P, Fureman A-L, Nilsson A-L, Boström J, Kriström B, Ekström K, Hwa V, Rosenfeld RG, Carlsson-Skwirut C 2009Anovel missense mutation of the ALSIGF gene causing a L172F substitution in LRR6 is associated with short stature in two Swedish children homozygous or compound heterozygous for the mutation. Horm Res 72(Suppl 3): Abstract P01-063:86.
184. Gallego-Gomez E, Sanchez del Pozo J, Cruz Rojo J, Zurita-Muñoz O, Gracia-Bouthelier R, Heath KE, Campos-Barros A 2009 Novel compound heterozygous IGFALS mutation associated with impaired postnatal growth and low circulating IGF-I and IGFBP-3 levels. Horm Res 72(Suppl 3):Abstract P01-076:90-91.